Browsing by Author "Hilmioglu, Fatih"

Now showing 1 - 10 of 10

Clinical Course of Inflammatory Bowel Disease and Primary Sclerosing Cholangitis after Liver Transplantation
(2018) Dagli, Ulku; Etik, Digdem Ozer; Akdur, Aydincan; Selcuk, Haldun; Hilmioglu, Fatih; Boyacioglu, Sedat; Moray, Gokhan; Haberal, Mehmet; 0000-0003-0664-0976; 0000-0002-4724-0728; 0000-0002-8726-3369; 0000-0002-8445-6413; 0000-0002-6440-5686; 0000-0002-9370-1126; 0000-0003-2498-7287; 0000-0002-3462-7632; S-4068-2018; AAJ-4707-2021; AAA-3068-2021; AAJ-6976-2021; AAJ-4437-2021; AAE-7637-2021; AAE-1041-2021; AAJ-8097-2021
The effect of bleomycin embolization on symptomatic improvement and hemangioma size among patients with giant liver hemangiomas
(2018) Kirnap, Mahir; Boyvat, Fatih; Boyacioglu, Sedat; Hilmioglu, Fatih; Moray, Gokhan; Haberal, Mehmet; 0000-0003-2498-7287; AAH-9198-2019
Efficacy and Tolerability of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in Kidney Transplant Recipients
(2018) Suna, Nuretdin; Etik, Digdem Ozer; Ocal, Serkan; Selcuk, Haldun; Dagli, Ulku; Hilmioglu, Fatih; Boyacioglu, Sedat; Haberal, Mehmet; https://orcid.org/0000-0001-6234-7788; https://orcid.org/0000-0003-3719-9482; https://orcid.org/0000-0002-8445-6413; https://orcid.org/0000-0002-6440-5686; https://orcid.org/0000-0002-9370-1126; https://orcid.org/0000-0002-3462-7632; AAI-8822-2021; ABH-4817-2020; AAJ-6976-2021; AAJ-4437-2021; AAE-7637-2021; AAJ-8097-2021
Extraordinary biliary variant
(2017) Suna, Nuretdin; Etik, Digdem Ozer; Ocal, Serkan; Selcuk, Haldun; Hilmioglu, Fatih; Boyacioglu, Sedat; 0000-0003-3719-9482; 0000-0002-9370-1126; 0000-0002-6440-5686; 0000-0002-4724-0728; 0000-0002-8445-6413; 0000-0001-6234-7788; 28336501; ABH-4817-2020; AAE-7637-2021; AAJ-4437-2021; AAJ-4707-2021; AAJ-6976-2021; AAI-8822-2021
Hepatocellular Carcinoma with Cardiac Cirrhosis After the Fontan Procedure
(2018) Suna, Nuretdin; Etik, Digdem Ozer; Ocal, Serkan; Hilmioglu, Fatih; 0000-0001-6234-7788; 0000-0002-4724-0728; 0000-0002-6440-5686; 0000-0003-3719-9482; 29373356; AAI-8822-2021; AAJ-4707-2021; AAJ-4437-2021; ABH-4817-2020
Liver Biopsy Results in Potential Donor Evaluation in Living Related Liver Transplant
(2018) Soy, Ebru H. Ayvazoglu; Boyvat, Fatih; Ozdemir, B. Handan; Haberal, Nihan; Hilmioglu, Fatih; Haberal, Mehmet; 0000-0002-0993-9917; 0000-0002-7528-3557; 0000-0001-9852-9911; 0000-0002-6440-5686; 0000-0002-3462-7632; 29527988; AAC-5566-2019; F-4230-2011; X-8540-2019; AAK-4587-2021; AAJ-4437-2021; AAJ-8097-2021
Objectives: The number of living-donor liver transplants has been increasing due to the growing discrepancy between the number of patients on wait lists for liver transplant and the availability of deceased donations. Evaluations of potential liver donors should ensure the safety of the surgical procedure for both the donor and recipient. Liver biopsy is the criterion standard for selecting optimal donors. In this study, we evaluated the importance of preoperative liver biopsy in selecting donor candidates. Materials and Methods: We evaluated the data of 612 living-related liver donor candidates who received liver biopsies between January 2001 and June 2017 at our center. Results: In the 612 liver donor candidates (328 male, 284 female; age range, 18-69 years), 416 liver biopsies (68%) were reported as normal and 196 liver biopsies (32%) had pathologic findings. Of 196 donors with pathologic findings, 86 (44%) had fatty changes and 24 (12%) had portal inflammation. Conclusions: The high rate of pathologic findings in liver biopsy of healthy-appearing donor candidates indicated the importance of liver biopsy in the preoperative evaluation of donors.
A rare cause of gastric outlet obstruction
(2017) Suna, Nurettin; Ocal, Serkan; Etik, Digdem Ozer; Selcuk, Haldun; Hilmioglu, Fatih; Boyacioglu, Sedat; 0000-0001-6234-7788; 0000-0003-3719-9482; 0000-0002-8445-6413; 0000-0002-4724-0728; 0000-0002-6440-5686; 0000-0002-9370-1126; 28705787; AAI-8822-2021; ABH-4817-2020; AAJ-6976-2021; AAJ-4707-2021; AAJ-4437-2021; AAE-7637-2021
Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients
(2019) Etik, Digdem Ozer; Suna, Nuretdin; Ocal, Serkan; Selcuk, Haldun; Dagli, Ulku; Colak, Turan; Hilmioglu, Fatih; Boyacioglu, Ahmet Sedat; Haberal, Mehmet; 0000-0003-3719-9482; 0000-0003-0664-0976; 0000-0002-9370-1126; 30719954; ABH-4817-2020; AAE-7637-2021; S-4068-2018
Objectives: The introduction of direct-acting antiviral agents has allowed significant chances for treatment for difficult-to-treat populations. This study aimed to investigate the efficacy, tolerability, and safety of these therapies in both patients with end-stage renal disease and kidney transplant recipients with chronic hepatitis C virus infection. Materials and Methods: This study was a retrospective analysis with prospective follow-up of patients. The antiviral combination of ombitasvir 25 mg, paritaprevir 75 mg, ritonavir 50 mg, and dasabuvir 50 mg was prescribed to patients with end-stage renal disease or kidney transplant recipients with noncirrhotic or compensated cirrhotic liver disease. The other antiviral combination consisted of sofosbuvir 400 mg and ledipasvir 90 mg, which was recommended to patients with decompensated cirrhosis or those who could not tolerate the first combination regimen. Ribavirin was given to all patients with genotype 1a hepatitis C virus infection. All clinical and laboratory data were recorded at week 4, at end of the treatment, and at 12 weeks after completion of treatment. Results: In terms of efficacy, sustained virologic response at 12 weeks was achieved in 94% of patients in the end-stage renal disease group and 92% of patients in the kidney transplant group. In terms of tolerability, antiviral treatment was well tolerated in both groups. Cardiac arrest and cerebrovascular accident were seen in the end-stage renal disease group; severe mucositis and glossitis were seen in the kidney transplant group. Hospitalization was needed in 2 patients for treatment of drug interactions with tacrolimus and sirolimus. Renal allograft function worsened in 2 patients, with 1 patient having biopsyproven antibody-mediated rejection. Conclusions: We observed great efficacy and safety in both kidney transplant recipients and patients with end-stage renal disease with these agents in treatment of chronic hepatitis C. However, clinicians should remain aware of drug interactions and adverse events in this fragile patient population.
Successful Treatment with Direct-Acting Antiviral Agents of Hepatitis C in the Setting of End-Stage Renal Disease
(2018) Etik, Digdem Ozer; Suna, Nuretdin; Ocal, Serkan; Selcuk, Haldun; Dagli, Ulku; Colak, Turan; Hilmioglu, Fatih; Boyacioglu, Sedat; Haberal, Mehmet; 0000-0002-4724-0728; 0000-0001-6234-7788; 0000-0003-3719-9482; 0000-0002-8445-6413; 0000-0003-0664-0976; 0000-0002-8372-7840; 0000-0002-6440-5686; 0000-0002-9370-1126; 0000-0002-3462-7632; AAJ-4707-2021; AAI-8822-2021; ABH-4817-2020; AAJ-6976-2021; S-4068-2018; AAJ-8554-2021; AAJ-4437-2021; AAE-7637-2021; AAJ-8097-2021
When abdominal pain knocks the door: an unusual presentation of chronic lymphocytic leukemia
(2019) Etik, Digdem Ozer; Suna, Nuretdin; Borcek, Pelin; Hilmioglu, Fatih; 31198573
A 67-year-old man presented non-specific abdominal pain. Polypoid mass at appendiceal orifice in the cecum was found on endoscopic investigation without appendicitis sign. Histopathology elucidated underlying mucosal infiltration that was chronic lymphocytic leukemia. This is an isolated and unusual gastrointestinal involvement of hematologic disorder in an older patient.